Douglas Schlichting

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Peter C. Taylor, Edward Keystone, Désirée van der Heijde et al. · New England Journal of Medicine · 2017 · 951 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Mark C. Genovese, Joel Kremer, Omid Zamani et al. · New England Journal of Medicine · 2016 · 621 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

Roy Fleischmann, Michael Schiff, Désirée van der Heijde et al. · Arthritis & Rheumatology · 2016 · 423 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen et al. · Annals of the Rheumatic Diseases · 2016 · 399 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Edward Keystone, Peter C. Taylor, Edit Drescher et al. · Annals of the Rheumatic Diseases · 2014 · 282 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13